Phase III: Colorectal Cancer
ClinicalTrials.gov Id: NCT01309126
Biothera has initiated a Phase III clinical trial to evaluate cetuximab (Erbitux®) with and without Imprime PGG® in colorectal cancer patients. The open-label, randomized study will enroll an estimated 795 patients and will be conducted at approximately 50 locations worldwide.
Status: Recruiting.
Countries currently participating in the study include: U.S., Germany and France. Please check for future country additions. Blue sites on the map indicate locations that are currently enrolling patients. Red sites indicate locations that will be active soon.